Protect and strengthen democratic society today and for the future. Invest in AllSides
Protect and strengthen democratic society today and for the future. Invest in AllSides
Protect and strengthen democratic society today and for the future. Invest in AllSides

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!
See some of the most popular below:

Want to see more?
Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!
See some of the most popular below:

Want to see more?
Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!
See some of the most popular below:

Want to see more?
Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

Invest in

Invest in

Invest in

What America Do We Want to Be?

Join Living Room Conversations, our civil dialogue partner, and America Indivisible for a nationwide conversation on April 13, Thomas Jefferson’s 276th birthday. "Reckoning with Jefferson: A Nationwide Conversation on Race, Religion, and the America We Want to Be" will be held via in-person and online video discussions. Sign up today!

What America Do We Want to Be?

Join Living Room Conversations, our civil dialogue partner, and America Indivisible for a nationwide conversation on April 13, Thomas Jefferson’s 276th birthday. "Reckoning with Jefferson: A Nationwide Conversation on Race, Religion, and the America We Want to Be" will be held via in-person and online video discussions. Sign up today!

What America Do We Want to Be?

Join Living Room Conversations, our civil dialogue partner, and America Indivisible for a nationwide conversation on April 13, Thomas Jefferson’s 276th birthday. "Reckoning with Jefferson: A Nationwide Conversation on Race, Religion, and the America We Want to Be" will be held via in-person and online video discussions. Sign up today!

Practical, engaging webinars designed to transform how you approach current events and facilitate productive classroom discussions.

The Art of Discussion - Civic Learning Week

Wednesday March 12, 2025 | 6:00 PM Eastern Time

Learn how to facilitate respectful dialogue across political and social divides using Mismatch, our platform for connecting students with diverse viewpoints.

Register for the webinar PD Benefits Page
 

Practical, engaging webinars designed to transform how you approach current events and facilitate productive classroom discussions.

The Art of Discussion - Civic Learning Week

Wednesday March 12, 2025 | 6:00 PM Eastern Time

Learn how to facilitate respectful dialogue across political and social divides using Mismatch, our platform for connecting students with diverse viewpoints.

Register for the webinar PD Benefits Page
 

Practical, engaging webinars designed to transform how you approach current events and facilitate productive classroom discussions.

The Art of Discussion - Civic Learning Week

Wednesday March 12, 2025 | 6:00 PM Eastern Time

Learn how to facilitate respectful dialogue across political and social divides using Mismatch, our platform for connecting students with diverse viewpoints.

Register for the webinar PD Benefits Page
 

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!

See some of the most popular below:

Want to see more?

Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!

See some of the most popular below:

Want to see more?

Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

See How AllSides Rates Other Media Outlets

We have rated the bias of nearly 600 outlets and writers!

See some of the most popular below:

Want to see more?

Check out the AllSides Media Bias Chart, or go to our Media Bias Ratings page to see everything.

 

 

 

Support AllSides

Please consider becoming a sustaining member or making a one-time donation to help keep AllSides online.

Become a Sustaining Member

Make a one-time donation.

Support AllSides

Please consider becoming a sustaining member or making a one-time donation to help keep AllSides online.

Become a Sustaining Member

Make a one-time donation.

Support AllSides

Please consider becoming a sustaining member or making a one-time donation to help keep AllSides online.

Become a Sustaining Member

Make a one-time donation.

https://www.factcheck.org/2021/09/scicheck-ongoing-clinical-trials-will-decide-…
Type of Content
Approved Story
1
Format
Region
News Item Format
Standard

The Food and Drug Administration has not approved the use of ivermectin, an antiparasitic medication, to treat or prevent COVID-19, the disease caused by the SARS-CoV-2 virus. Ivermectin is approved for human use only to treat some conditions caused by parasites, such as intestinal strongyloidiasis and onchocerciasis, head lice, and skin conditions. 

Although the National Institutes of Health counts over 70 studies evaluating the safety and effectiveness of ivermectin to treat or prevent COVID-19 in humans, the FDA says “currently available data do not show ivermectin is effective against COVID-19,” and using the medication for this purpose in humans or animals “can be highly dangerous” in some instances.

Yet, at a town hall, Kentucky Sen. Rand Paul said the drug was not officially available because researchers were “unwilling to objectively study” the use of ivermectin to treat COVID-19 out of “hatred” for former President Donald Trump. 

“The hatred for Trump deranged these people so much that they’re unwilling to objectively study it,” Paul told constituents on Friday, Aug. 27, after a woman asked why ivermectin wasn’t more available, according to the Cincinnati Enquirer’s report of the gathering. “So someone like me that’s in the middle on it, I can’t tell you because they will not study ivermectin.”

In a subsequent opinion piece published by the Enquirer on Sept. 8, Paul said the paper did not report what he said “accurately.” He said his point was that “we don’t yet know the full story on whether” ivermectin “is effective,” and he acknowledged the drug was in “several studies including a Phase 3 trial for COVID right now.” “I never recommended anyone take Ivermectin,” he wrote.